Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $1,049,700.00 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $104.97, for a total transaction of $1,049,700.00. Following the transaction, the senior vice president directly owned 14,219 shares in the company, valued at $1,492,568.43. This trade represents a 41.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

  • On Monday, October 12th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.60, for a total value of $805,919.40.
  • On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.75, for a total value of $51,034.75.
  • On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $53,597.60.
  • On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total value of $872,403.57.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA opened at $105.35 on Monday. Oruka Therapeutics, Inc. has a 52-week low of $25.23 and a 52-week high of $115.51. The business’s 50 day simple moving average is $89.68 and its two-hundred day simple moving average is $72.36. The firm has a market cap of $7.14 billion, a P/E ratio of -49.93 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). On average, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ORKA shares. Guggenheim restated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 26th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. Finally, Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.80.

Get Our Latest Stock Analysis on ORKA

Top Oruka Therapeutics Stories

Here are a few of the latest stories about ORKA:

  • Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
  • Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
  • Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ORKA. Nykredit A S bought a new position in Oruka Therapeutics during the 2nd quarter valued at $29,000. GAMMA Investing LLC grew its stake in shares of Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after acquiring an additional 250 shares in the last quarter. Orion Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $91,000. Sterling Capital Management LLC grew its stake in shares of Oruka Therapeutics by 839.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after acquiring an additional 1,485 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Oruka Therapeutics by 178.5% in the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after acquiring an additional 2,033 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

(Get Free Report)

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Recommended Stories

Insider Buying and Selling by Quarter for Oruka Therapeutics (NASDAQ:ORKA)

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.